This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

OvaScience Co-Founder David Sinclair, Ph.D., Selected By TIME As One Of The 100 Most Influential People In The World

Stocks in this article: OVAS

OvaScienceSM, (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today announced that the Company’s scientific Co-Founder,  David Sinclair, Ph.D., has been selected for the 2014 TIME 100, TIME’s annual list of the 100 most influential people in the world. Dr. Sinclair’s extensive research on aging and the key role of mitochondria (the energy source for all cells) contributed to OvaScience’s foundational egg precursor cell (EggPC SM) technology platform. The Company expects to launch its first fertility product, AUGMENT SM, in international in vitro fertilization (IVF) clinics in 2014. AUGMENT is designed to improve egg quality and the success of IVF by enhancing mitochondrial function.

“We congratulate Dr. Sinclair on his recognition by TIME for his groundbreaking research on aging, which is enabling the development of new treatments for conditions of aging, such as infertility,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “Our team at OvaScience is working with Dr. Sinclair to gain further insights about the impact of aging on egg quality as we continue to develop treatments for female infertility.”

Dr. Sinclair is a Professor in the Department of Genetics at Harvard Medical School and a con-joint Professor in the Department of Physiology and Pharmacology at the University of New South Wales. Dr. Sinclair was recruited to Harvard Medical School in 1999 where his laboratory’s research has focused primarily on understanding the role of sirtuins in disease and aging, with associated interests in energy metabolism, mitochondria, neurodegeneration, and cancer. Dr. Sinclair is the co-Director of the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging and a Senior Scholar of the Ellison Medical Foundation.

Dr. Sinclair has published more than 126 scientific papers. His December 2013 paper in Cell underscored the critical role of mitochondrial function in aging, and described certain molecules that can improve mitochondrial function, to which OvaScience has exclusive rights in fertility. Dr. Sinclair is the 2014 Australian Society for Medical Research (ASMR) medalist, an award which recognizes his career contributions to medical research, and an honor shared by past Nobel Prize winners. He is also the co-founder of several biotechnology companies and is on the scientific advisory board of several others.

Earlier in his career, Dr. Sinclair worked as a postdoctoral researcher at M.I.T. with Dr. Leonard Guarente where he co-discovered a cause of aging for yeast and the role of Sir2 in DNA repair and aging. He obtained his Ph.D. in Biochemistry and Molecular Genetics at the University of New South Wales, Sydney in 1995.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs